106 related articles for article (PubMed ID: 16965332)
1. A frameshift mutation in peroxisome-proliferator-activated receptor-gamma in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367).
Hegele RA; Ur E; Ransom TP; Cao H
Clin Genet; 2006 Oct; 70(4):360-2. PubMed ID: 16965332
[No Abstract] [Full Text] [Related]
2. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
[TBL] [Abstract][Full Text] [Related]
3. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
[TBL] [Abstract][Full Text] [Related]
4. Vascular placental abnormalities and newborn death in a pregnant diabetic woman with familial partial lipodystrophy type 3: a possible role for peroxisome proliferator-activated receptor γ.
Castell AL; Hiéronimus S; Lascols O; Fournier T; Fénichel P
Diabetes Metab; 2012 Oct; 38(4):367-9. PubMed ID: 22559930
[TBL] [Abstract][Full Text] [Related]
5. Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy.
Jeninga EH; van Beekum O; van Dijk AD; Hamers N; Hendriks-Stegeman BI; Bonvin AM; Berger R; Kalkhoven E
Mol Endocrinol; 2007 May; 21(5):1049-65. PubMed ID: 17312272
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
[TBL] [Abstract][Full Text] [Related]
7. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
Lüdtke A; Buettner J; Schmidt HH; Worman HJ
J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
[TBL] [Abstract][Full Text] [Related]
8. Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3.
Miehle K; Porrmann J; Mitter D; Stumvoll M; Glaser C; Fasshauer M; Hoffmann K
Clin Endocrinol (Oxf); 2016 Jan; 84(1):141-8. PubMed ID: 26119484
[TBL] [Abstract][Full Text] [Related]
9. Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient.
Chen X; Ma Z; Chen P; Song X; Li W; Yu X; Xie J
Front Endocrinol (Lausanne); 2022; 13():830708. PubMed ID: 35422762
[TBL] [Abstract][Full Text] [Related]
10. A clinical link between peroxisome proliferator-activated receptor γ and the renin-angiotensin system.
Sigmund CD
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):676-8. PubMed ID: 23486770
[TBL] [Abstract][Full Text] [Related]
11. Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660).
Lanktree M; Cao H; Rabkin SW; Hanna A; Hegele RA
Clin Genet; 2007 Feb; 71(2):183-6. PubMed ID: 17250669
[No Abstract] [Full Text] [Related]
12. Familial partial lipodystrophy type 3: a new mutation on the PPARG gene.
Lau E; Carvalho D; Oliveira J; Fernandes S; Freitas P
Hormones (Athens); 2015; 14(2):317-20. PubMed ID: 26158656
[No Abstract] [Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma-ligand-binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration.
Shoaito H; Chauveau S; Gosseaume C; Bourguet W; Vigouroux C; Vatier C; Pienkowski C; Fournier T; Degrelle SA
J Cell Mol Med; 2020 Jul; 24(13):7660-7669. PubMed ID: 32519441
[TBL] [Abstract][Full Text] [Related]
14. Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.
Demir T; Onay H; Savage DB; Temeloglu E; Uzum AK; Kadioglu P; Altay C; Ozen S; Demir L; Cavdar U; Akinci B
Diabet Med; 2016 Oct; 33(10):1445-50. PubMed ID: 26756202
[TBL] [Abstract][Full Text] [Related]
15. The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy.
Padova G; Prudente S; Vinciguerra F; Sudano D; Baratta R; Bellacchio E; Trischitta V; Vallone A; Sciacca L; Frittitta L
Acta Diabetol; 2020 May; 57(5):589-596. PubMed ID: 31863320
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophy.
Lori C; Pasquo A; Montanari R; Capelli D; Consalvi V; Chiaraluce R; Cervoni L; Loiodice F; Laghezza A; Aschi M; Giorgi A; Pochetti G
Acta Crystallogr D Biol Crystallogr; 2014 Jul; 70(Pt 7):1965-76. PubMed ID: 25004973
[TBL] [Abstract][Full Text] [Related]
17. Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPARγ mutants.
Broekema MF; Savage DB; Monajemi H; Kalkhoven E
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 May; 1864(5):715-732. PubMed ID: 30742913
[TBL] [Abstract][Full Text] [Related]
18. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3).
Francis GA; Li G; Casey R; Wang J; Cao H; Leff T; Hegele RA
BMC Med Genet; 2006 Jan; 7():3. PubMed ID: 16412238
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation.
Iizaka T; Kodama E; Mikura K; Iida T; Imai H; Hashizume M; Kigawa Y; Sugisawa C; Tadokoro R; Endo K; Otsuka F; Isoda M; Ebihara K; Ishibashi S; Nagasaka S
Endocr J; 2023 Jan; 70(1):69-76. PubMed ID: 36171144
[TBL] [Abstract][Full Text] [Related]
20. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy.
Al-Shali K; Cao H; Knoers N; Hermus AR; Tack CJ; Hegele RA
J Clin Endocrinol Metab; 2004 Nov; 89(11):5655-60. PubMed ID: 15531525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]